Verastem (VSTM) Revenue & Revenue Breakdown
Verastem Revenue Highlights
Latest Revenue (Q)
$10.00M
Main Segment (Y)
Sale of COPIKTRA license and related assets
Verastem Revenue by Period
Verastem Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $2.60M | 26.45% |
| 2021-12-31 | $2.05M | -97.68% |
| 2020-12-31 | $88.52M | 407.08% |
| 2019-12-31 | $17.46M | -34.67% |
| 2018-12-31 | $26.72M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | - |
Verastem generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Verastem Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $10.00M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $114.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $2.60M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $2.60M | 376.33% |
| 2021-12-31 | $545.00K | 27150.00% |
| 2021-09-30 | $2.00K | -99.60% |
| 2021-06-30 | $500.00K | -50.30% |
| 2021-03-31 | $1.01M | 98.81% |
| 2020-12-31 | $506.00K | -99.36% |
| 2020-09-30 | $78.65M | 1726.03% |
| 2020-06-30 | $4.31M | -14.81% |
| 2020-03-31 | $5.06M | 39.82% |
| 2019-12-31 | $3.62M | -59.96% |
| 2019-09-30 | $9.03M | 188.01% |
| 2019-06-30 | $3.14M | 87.67% |
| 2019-03-31 | $1.67M | 38.10% |
| 2018-12-31 | $1.21M | -92.20% |
| 2018-09-30 | $15.51M | 55.08% |
| 2018-06-30 | $10.00M | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | - |
Verastem generated $10.00M in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Verastem Revenue Breakdown
Verastem Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Sale of COPIKTRA license and related assets | $2.60M | - | - | - | - |
| Copiktra license and related assets | - | $1.45M | - | - | - |
| Government rebates and other incentives | - | $67.00K | - | - | - |
| Trade discounts and allowances | - | $23.00K | - | - | - |
| Returns | - | $31.00K | - | - | - |
| Product Revenue And Allowances Returns | - | - | $31.00K | $76.00K | $2.00K |
| Product Revenue Reserves And Allowances Trade Discounts And Allowances | - | - | $23.00K | $111.00K | $29.00K |
| Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees | - | - | $2.08M | $255.00K | $88.00K |
| Product Revenue Reserves And Allowances Government Rebates And Other Incentives | - | - | $67.00K | $372.00K | $157.00K |
Verastem's latest annual revenue breakdown by segment (product or service), as of Dec 22: Sale of COPIKTRA license and related assets (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of COPIKTRA license and related assets | $2.60M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Copiktra license and related assets | - | $545.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Transition Services Revenue | - | - | $2.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Copiktra License And Related Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Revenue Reserves And Allowances Government Rebates And Other Incentives | - | - | - | - | $67.00K | $189.00K | $320.00K | $455.00K | $950.00K | $544.00K | $217.00K | $199.00K | $282.00K | $128.00K | $29.00K |
| Product Revenue And Allowances Returns | - | - | - | $28.00K | $28.00K | $25.00K | $126.00K | $326.00K | $123.00K | $5.00K | $71.00K | $8.00K | $4.00K | $1.00K | $1.00K |
| Product Revenue Reserves And Allowances Trade Discounts And Allowances | - | - | - | $4.00K | $4.00K | $138.00K | $147.00K | $94.00K | $137.00K | $695.00K | $122.00K | $52.00K | $43.00K | $42.00K | $27.00K |
| Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees | - | - | - | - | - | $270.00K | $296.00K | $135.00K | $239.00K | $1.85M | $281.00K | $153.00K | $104.00K | $48.00K | $72.00K |
Verastem's latest quarterly revenue breakdown by segment (product or service), as of Mar 22: Sale of COPIKTRA license and related assets (100.00%).
Verastem Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of COPIKTRA license and related assets | $2.60M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Copiktra license and related assets | - | $545.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Transition Services Revenue | - | - | $2.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Copiktra License And Related Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Revenue And Allowances Returns | - | - | - | $28.00K | $28.00K | $25.00K | $126.00K | $326.00K | $123.00K | $5.00K | $71.00K | $8.00K | $4.00K | $1.00K | $1.00K |
| Product Revenue Reserves And Allowances Government Rebates And Other Incentives | - | - | - | - | $67.00K | $189.00K | $320.00K | $455.00K | $950.00K | $544.00K | $217.00K | $199.00K | $282.00K | $128.00K | $29.00K |
| Product Revenue Reserves And Allowances Trade Discounts And Allowances | - | - | - | $4.00K | $4.00K | $138.00K | $147.00K | $94.00K | $137.00K | $695.00K | $122.00K | $52.00K | $43.00K | $42.00K | $27.00K |
| Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees | - | - | - | - | - | $270.00K | $296.00K | $135.00K | $239.00K | $1.85M | $281.00K | $153.00K | $104.00K | $48.00K | $72.00K |
Verastem's latest quarterly revenue breakdown by geography, as of Mar 22: Sale of COPIKTRA license and related assets (100.00%).
VSTM Revenue FAQ
What is Verastem’s yearly revenue?
Verastem's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $2.6M, representing an increase of 26.45% compared to 2021. VSTM's yearly revenue for 2021 was $2.05M, representing a decrease of -97.68% compared to 2020.
What is Verastem’s quarterly revenue?
Verastem's quarterly revenue for Q2 2024 was $10M, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). VSTM's quarterly revenue for Q4 2023 was $114K, a 100.00% increase from the previous quarter (Q3 2023), and a -95.61% decrease year-over-year (Q4 2022).
What is Verastem’s revenue growth rate?
Verastem's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.
What are Verastem’s revenue streams?
Verastem's revenue streams in c 22 are Sale of COPIKTRA license and related assets
What is Verastem’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Verastem was Sale of COPIKTRA license and related assets. This segment made a revenue of $2.6M, representing 100.00% of the company's total revenue.